Last reviewed · How we verify
cyclophosphamide, methotrexate, and fluorouracil
At a glance
| Generic name | cyclophosphamide, methotrexate, and fluorouracil |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (PHASE1)
- Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer (PHASE2)
- Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
- Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
- Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients (PHASE3)
- Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: